Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Vivek Subbiah, Tina Cascone, Kenneth R. Hess, Ishwaria Mohan Subbiah, Sarah Nelson, Naoto Morikawa, Monique B. Nilsson, Tarak Bhatt, Siraj Ali, William Nassib William, Victoria M. Raymond, Richard B. Lanman, David Paul Carbone, Ravi Salgia, Taofeek Kunle Owonikoko, George R. Simon, Funda Meric-Bernstam, Robert Charles Doebele, John Heymach
Institutions: The University of Texas MD Anderson Cancer Center, University of Colorado Anschutz, Iwate Medical University, Foundation Medicine (United States), Guardant (United States), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University of Chicago, Emory University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891362051